Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 2:15:1385135.
doi: 10.3389/fimmu.2024.1385135. eCollection 2024.

Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination

Hakjun Hyun  1 , Eliel Nham  2   3   4 , Hye Seong  2   3   4 , Jin Gu Yoon  2   3   4 , Ji Yun Noh  2   3   4 , Hee Jin Cheong  2   3   4 , Woo Joo Kim  2   3   4 , Sun Kyung Yoon  5 , Se-Jin Park  5 , WonSeok Gwak  5 , June-Woo Lee  5 , Byoungguk Kim  5 , Joon Young Song  2   3   4
Affiliations

Long-term humoral and cellular immunity against vaccine strains and Omicron subvariants (BQ.1.1, BN.1, XBB.1, and EG.5) after bivalent COVID-19 vaccination

Hakjun Hyun et al. Front Immunol. .

Abstract

Background: The assessment of long-term humoral and cellular immunity post-vaccination is crucial for establishing an optimal vaccination strategy.

Methods: This prospective cohort study evaluated adults (≥18 years) who received a BA.4/5 bivalent vaccine. We measured the anti-receptor binding domain immunoglobulin G antibody and neutralizing antibodies (NAb) against wild-type and Omicron subvariants (BA.5, BQ.1.1, BN.1, XBB.1 and EG.5) up to 9 months post-vaccination. T-cell immune responses were measured before and 4 weeks after vaccination.

Results: A total of 108 (28 SARS-CoV-2-naïve and 80 previously infected) participants were enrolled. Anti-receptor binding domain immunoglobulin G (U/mL) levels were higher at 9 months post-vaccination than baseline in SAR-CoV-2-naïve individuals (8,339 vs. 1,834, p<0.001). NAb titers against BQ.1.1, BN.1, and XBB.1 were significantly higher at 9 months post-vaccination than baseline in both groups, whereas NAb against EG.5 was negligible at all time points. The T-cell immune response (median spot forming unit/106 cells) was highly cross-reactive at both baseline (wild-type/BA.5/XBB.1.5, 38.3/52.5/45.0 in SARS-CoV-2-naïve individuals; 51.6/54.9/54.9 in SARS-CoV-2-infected individuals) and 4 weeks post-vaccination, with insignificant boosting post-vaccination.

Conclusion: Remarkable cross-reactive neutralization was observed against BQ.1.1, BN.1, and XBB.1 up to 9 months after BA.4/5 bivalent vaccination, but not against EG.5. The T-cell immune response was highly cross-reactive.

Keywords: EG.5; SARS-CoV-2; cellular immunity; cross-reactivity; durability; humoral immunity; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Anti-receptor binding domain immunoglobulin G antibodies after BA.4/5 bivalent mRNA COVID-19 vaccination. The columns represent the geometric mean titers and black bars represent 95% confidence intervals. Statistically significant p-values are marked with asterisks (*p < 0.05, ****p < 0.0001). GMT, geometric mean titer; IgG, immunoglobulin G; ns, not significant; RBD, receptor binding domain.
Figure 2
Figure 2
Comparison of neutralizing activity against wild-type and Omicron subvariants at different time points after BA.4/5 bivalent mRNA COVID-19 vaccination. The columns represent the geometric mean titers and black bars represent 95% confidence intervals. Time points are presented as T0 (baseline), T1 (4 weeks after vaccination), T2 (3 months after vaccination), and T4 (9 months after vaccination). Statistically significant p-values are marked with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). ND50, 50% neutralization dilution; ns, not significant; WT, wild-type.
Figure 3
Figure 3
Comparison of neutralizing activity against wild-type and Omicron subvariants by prior SARS-CoV-2 infection after BA.4/5 bivalent mRNA COVID-19 vaccination. The columns represent the geometric mean titers and black bars represent 95% confidence intervals. Statistically significant p-values are marked with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). ND50, 50% neutralization dilution; ns, not significant; WT, wild-type.
Figure 4
Figure 4
T-cell immune responses against wild-type, BA.5, and XBB.1.5 subvariants of SARS-CoV-2 at baseline (pre-vaccination) and 4 weeks (post-vaccination) after BA.4/5 bivalent mRNA COVID-19 vaccination. The black bar represents the median with interquartile range. ELISpot, enzyme-linked ImmunoSpot; IFN-γ, interferon-γ; ns, not significant; SFU, spot forming unit; WT, wild-type.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization . WHO COVID-19 dashboard(2024). Available online at: https://data.who.int/dashboards/covid19/cases?n=c (Accessed 12 February 2024).
    1. Hodcroft EB. CoVariants: SARS-CoV-2 mutations and variants of interest(2024). Available online at: https://covariants.org/per-country?region=World (Accessed 25 January 2024).
    1. Palacios-Pedrero MA, Jansen JM, Blume C, Stanislawski N, Jonczyk R, Molle A, et al. . Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nat Aging. (2022) 2:896–905. doi: 10.1038/s43587-022-00292-y - DOI - PMC - PubMed
    1. Zaher K, Basingab F, Alrahimi J, Basahel K, Aldahlawi A. Gender differences in response to COVID-19 infection and vaccination. Biomedicines. (2023) 11. doi: 10.3390/biomedicines11061677 - DOI - PMC - PubMed
    1. Notarte KI, Catahay JA, Peligro PJ, Velasco JV, Ver AT, Guerrero JJ, et al. . Humoral response in hemodialysis patients post-SARS-CoV-2 mRNA vaccination: A systematic review of literature. Vaccines. (2023) 11. doi: 10.3390/vaccines11040724 - DOI - PMC - PubMed

MeSH terms

Supplementary concepts